Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

[184 Pages Report]The overall vaccines market is expected to grow from USD 36.45 billion in 2018 to USD 50.42 billion by 2023, at a CAGR of 6.7% from 2018 to 2023. Market growth is attributed to the high prevalence of infectious diseases, growing support for vaccine R&D, investments into vaccine development, and a rising focus on immunization. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

Vaccines Market Research Report Industry Dynamics

Drivers

• High prevalence of infectious diseases
• Rising focus on immunization programs
• Growing government support for vaccine development
• Increasing company initiatives to enhance vaccine R&D

Restraints

• High cost of vaccine development

Opportunities

• High growth prospects in emerging markets
• Focus on therapeutic vaccines
• Use of adjuvants in vaccines

Challenges

• Inadequate access to vaccines
• Product recalls

High prevalence of infectious diseases drives the global vaccines market

The high prevalence of diseases, such as cholera, tuberculosis, hepatitis, and malaria will ensure strong demand for associated vaccines as well as R&D into more effective products for better adult and pediatric immunization. Currently, vaccines have been developed for 25 diseases, as against 70 types of deadly infectious agents.

The US FDA has licensed several vaccines to prevent infections, such as BioThrax (Emergent BioSolutions Inc., US) for the prevention of anthrax; Diphtheria & Tetanus Toxoids Adsorbed (Sanofi Pasteur Ltd., France); KINRIX (GlaxoSmithKline plc., UK) for immunization against diphtheria, tetanus, pertussis, and poliomyelitis; PedvaxHIB (Merck & Co., US) for diseases caused by Haemophilus influenza type B; and Afluria (CSL Limited, Australia) for the prevention of influenza.

Vaccines for diseases, such as cancer, Ebola, HIV, and malaria are currently in clinical trials to ensure their safety and efficacy.

The following are the major objectives of vaccines market research study.

• To define, describe, and forecast the global vaccines market on the basis of technology, type, disease indication, route of administration, and patient type
• To describe and forecast the vaccines market, in terms of value, by region–Asia, Europe, North America, and Rest of the World (RoW) along with their respective countries
• To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)
• To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders
• To analyze strategic approaches such as product launches, acquisitions, contracts, agreements, and partnerships in the vaccines market

During this research study, major players operating in the vaccines market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

To know about the assumptions considered for the study, download the pdf brochure

The vaccines market comprises a network of players involved in the research and product development; and distribution and sale. Key players considered in the analysis of the vaccines market are GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), Sanofi Pasteur (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), , Johnson & Johnson (US), MedImmune, LLC (US), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India).

Major Developments for Vaccines Market

• In 2016, Pfizer collaborated with Western Oncolytics to advance Western Oncolytics’ novel oncolytic vaccinia virus. This collaboration helped Pfizer to enhance its novel technology platform for cancer vaccines and strengthened its immuno-oncology portfolio.
• In 2016, GlaxoSmithKline collaborated with Vaccine Research Center at the NIH (US) to evaluate a new vaccine technology for Zika, known as SAM.
• In 2017, Merck collaborated with Premier, Inc. (US) to develop a preventive care model that seeks to improve adolescent and adult vaccination rates.
• In 2016, Sanofi Pasteur collaborated with The Oswaldo Cruz Foundation (Brazil) and WRAIR (US) to conduct R&D for a Zika vaccine.

Target Audience for Vaccines Market Research Report

• Manufacturers and suppliers of vaccines
• Research and development companies
• Medical research laboratories
• Academic medical centers and universities
• Research and consulting firms
• Venture capital firms

Vaccines Market Report Scope

Vaccines Market By Technology

• Conjugate Vaccines
• Inactivated and Subunit Vaccines              
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines

Vaccines Market By Type

• Monovalent Vaccines
• Multivalent Vaccines

Vaccines Market By Disease Indication

• Pneumococcal Disease
• Influenza
• DTP
• Hepatitis
• Human Papilloma Virus (HPV)
• Rotavirus
• Meningococcal Disease
• MMR (measles, mumps, and rubella)
• Varicella
• Polio
• Herpes Zoster
• Dengue
• Other Disease Indications

Vaccines Market By Route of Administration

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Other Routes of Administration

Vaccines Market By Patient Type

• Pediatrics
• Adults

Vaccines Market By Region

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe (RoE)
• Asia   
• Japan
• China
• India
• Rest of Asia (RoA)
• Rest of the World (RoW)

Critical questions which the vaccines market research report answers

• What are new diseases areas which the vaccines companies are exploring?
• Which are the key players in the market and how intense is the competition?

Available Customizations

Based on the given market data, MarketsandMarkets offers customizations in the reports as per the client’s specific requirements. The available customization options are as follows:

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Factors such as rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the vaccines market.

Vaccines are biological products used to enhance the immune response of a body to prevent diseases, such as cholera, typhoid, influenza, and hepatitis. Vaccines may contain weakened/killed microbes, toxins, or surface proteins for inducing immunity against specific diseases.

The vaccines market has been segmented, on the basis of technology, conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The market for conjugate vaccine is expected to grow at the highest CAGR between 2018 and 2023. The large share of this segment can primarily be attributed to the increasing government support and rising company investments for conjugate vaccine development.

The vaccines market in Asia is expected to grow at the highest CAGR during the forecast period. Asia is the fastest-growing market for vaccines. Increasing investments by companies in emerging countries, such as India and China is contributing to the growth of the market.

Monovalent vaccines drive the growth of vaccines market

Monovalent Vaccines

A monovalent vaccine is designed to combat a single disease and therefore contains a single strain of an antigen. A number of monovalent vaccines for diseases, such as malaria, Ebola, and dengue are undergoing clinical trials for testing their safety and efficacy. The growing prevalence of these diseases across the globe is a major factor driving market growth.

Multivalent Vaccines

A multivalent vaccine is designed to immunize against several strains or microorganisms, and therefore contains two or more strains/serotypes of the same antigen. Several combined multivalent vaccines are available in the market to protect against DTP, polio, and hepatitis, among other diseases.

Critical questions the report answers:

• Where will all these developments take the industry in the mid to long term?
• What are new diseases areas which the vaccines companies are exploring?

Vaccine development is a capital-intensive procedure. The development process (from in vitro research to marketing) takes 10–15 years and an investment of USD 800 million–USD 1 billion. Moreover, as the success rate of vaccine development is very low, manufacturers find it challenging to obtain initial investments and manage operational costs.

Furthermore, the storage and distribution cost of vaccines is higher than any other pharmaceutical product, as it requires specialized equipment and monitoring devices. The lack of proper storage and distribution facilities can deteriorate vaccine quality. Thus, the high cost of vaccine development and storage restrains market growth.

Key players in the market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), MedImmune, LLC (US), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi Pasteur (France), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Biological E (India), and Panacea Biotec (India). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new products in the market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst